Apogee Therapeutics (NASDAQ:APGE – Get Free Report) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Apogee Therapeutics and 4D Molecular Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Apogee Therapeutics | N/A | -20.05% | -19.33% |
| 4D Molecular Therapeutics | N/A | -24.06% | -22.52% |
Valuation & Earnings
This table compares Apogee Therapeutics and 4D Molecular Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apogee Therapeutics | N/A | N/A | -$83.99 million | ($2.07) | -27.20 |
| 4D Molecular Therapeutics | $20.22 million | 21.01 | -$100.84 million | ($2.30) | -3.55 |
Insider and Institutional Ownership
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Apogee Therapeutics and 4D Molecular Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apogee Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
| 4D Molecular Therapeutics | 0 | 1 | 8 | 0 | 2.89 |
Apogee Therapeutics presently has a consensus target price of $78.50, suggesting a potential upside of 39.43%. 4D Molecular Therapeutics has a consensus target price of $47.14, suggesting a potential upside of 476.67%. Given 4D Molecular Therapeutics’ higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Apogee Therapeutics.
Risk & Volatility
Apogee Therapeutics has a beta of 2.94, indicating that its share price is 194% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500.
Summary
Apogee Therapeutics beats 4D Molecular Therapeutics on 7 of the 12 factors compared between the two stocks.
About Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
